Equities

Clinical Laserthermia Systems AB

Clinical Laserthermia Systems AB

Actions
  • Price (SEK)6.57
  • Today's Change-0.63 / -8.75%
  • Shares traded322.14k
  • 1 Year change-69.36%
  • Beta0.7235
Data delayed at least 15 minutes, as of Jun 03 2024 13:37 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.

  • Revenue in SEK (TTM)10.83m
  • Net income in SEK-70.90m
  • Incorporated2006
  • Employees7.00
  • Location
    Clinical Laserthermia Systems ABScheelev. 2, building 405LUND 223 81SwedenSWE
  • Phone+46 46152100
  • Websitehttps://clinicallaser.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neodynamics AB (publ)327.31k-87.19m29.61m----0.6192--90.47-37.52-37.520.00421.470.00455.471.48---120.15-53.18-158.59-61.85-12,573.30---26,637.31-17,680.111.14-22.780.00--138.18---24.36---45.17--
Invent Medic Sweden AB6.91m-8.34m30.15m8.00--8.74--4.37-0.2176-0.21760.17980.08010.56732.143.79863,296.30-68.50-97.56-109.24-121.0677.2677.16-120.76-490.980.4874-16.360.3007--115.97177.5328.77---22.61--
VibroSense Dynamics AB2.08m-7.61m31.91m----3.19--15.37-0.5156-0.51560.13250.2920.18890.14419.78---69.18-46.24-85.81-53.0894.0285.61-366.26-551.223.09--0.00--22.8929.616.88---5.74--
ATTANA AB5.52m-11.54m32.98m10.00--1.90--5.97-0.0367-0.03670.01680.04470.1945-0.48512.16552,453.00-40.62-37.18-52.55-46.66129.03175.97-208.89-254.690.3496-5.530.1539---32.896.615.80--8.21--
SciBase Holding AB (publ)23.25m-55.59m46.73m27.00--0.835--2.01-0.5854-0.58540.24180.35930.40720.75032.89860,962.90-97.36-68.63-143.11-87.7769.0061.28-239.12-300.202.56-32.770.00--29.9327.50-28.75--5.15--
Scandinavian Real Heart AB0.00-71.66m48.40m11.00--0.6499-----0.7028-0.70280.000.76780.00----0.00-67.22-24.27-78.30-26.81--832.41---6,070.11---701.980.0945---100.00---385.97---25.76--
Scandinavian ChemoTech AB4.11m-19.26m48.90m6.00--4.81--11.89-1.28-1.280.26410.4240.23270.32241.36685,500.00-108.95-87.29-108.95-118.5539.00252.05-468.27-2,122.77---15.730.00--496.6219.137.28------
ProstaLund AB20.12m-18.55m49.48m6.00--0.9792--2.46-0.2534-0.25340.27450.65980.39120.432511.14---36.07-29.14-40.73-35.0171.0575.26-92.21-68.941.90-126.960.0255--27.5410.36-53.27--20.35--
Inhalation Sciences Sweden AB17.50m-4.74m51.27m8.00--3.96--2.93-0.3575-0.35751.370.85411.120.94655.422,188,000.00-30.46-27.93-43.51-43.8279.7771.13-27.10-48.022.63-3.800.0776--43.5526.3360.87------
Clinical Laserthermia Systems AB10.83m-70.90m56.51m7.00--1.20--5.22-15.31-15.312.006.000.217312.584.86---144.45-123.49-259.50-312.95-392.44-1,084.16-664.90-1,625.032.06-30.970.0094--31.9935.55-12.92--18.61--
iZafe Group AB5.00m-32.78m58.25m7.00--2.94--11.64-0.133-0.1330.02010.07910.1091.242.46714,857.10-71.38-52.17-82.09-69.40-10.99---655.02-487.500.6947--0.1174--149.93-24.79-36.76---41.66--
Kontigo Care AB29.47m775.00k67.30m10.0064.001.8814.812.280.03280.03281.171.120.6807--7.69--1.79-0.42142.55-0.619568.8466.312.63-0.5205--4.000.093--1.8016.95-92.68--44.94--
Glycorex Transplantation AB (publ)31.00m-29.54m70.44m15.00--1.82--2.27-0.40-0.400.41970.54850.39780.72834.601,347,652.00-37.91-11.30-47.48-13.1784.7991.60-95.30-33.241.20-118.900.2046---17.04-2.15-254.06---0.5593--
BBS-Bioactive Bone Substitutes Oyj0.00-39.77m83.87m----1.37-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
Data as of Jun 03 2024. Currency figures normalised to Clinical Laserthermia Systems AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
Evli Fund Management Co. Ltd.as of 30 Apr 2024413.000.01%
Data from 30 Apr 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.